Fusion Antibodies

FAB · AIM · Health Care · mcap £14m · 10.0p

Beta Briefing, track record and bull & bear case are not ready for Fusion Antibodies yet.

We follow 817 UK small caps and every one of their announcements – often hundreds per company. 53 companies are already wired into a briefing: browse them.

Financials · LTM to 31 Mar 26

Source: results 15 Sep 26 ↗

Going-concern uncertainty

Revenue: £2.1m
Operating profit: −£1.1m
Net income: −£1.1m
Free cash flow: −£1.2m
Net cash: £712k
Market cap: £12.5m
EV / EBIT: –
FCF yield: −9.4%
Price / book: 7.7×

Latest half-year · H1 Sep 25 vs H1 Sep 24 results 24 Nov 25 ↗

Revenue: £838k
Operating profit: −£540k
Net income: −£512k
Cash from operations: −£567k

Extracted automatically from the company's results announcements; check the source before relying on a figure. Not investment advice.

Income statement Cash flow Balance sheet

Annual Half-yearly

Latest report: FY Mar 26 (twelve months to 31 Mar 26), published 15 Sep 26 · read the results ↗

£m unless stated · newest first · italic = calculated (LTM, H2 = FY − H1) · hover a value for its source

	FY Mar 26	FY Mar 25
Revenue	2.1	2.0
Gross profit	1.2	0.4
EBITDA	–	(1.7)
Operating profit	(1.1)	(1.6)
Share-based payments	0.1	0.0
Finance costs	(0.0)	(0.0)
Profit before tax	(1.1)	(1.6)
Tax	–	0.1
Net income (owners)	(1.1)	(1.6)
EPS basic	(1.2p)	(1.7p)

	H2 Mar 26	H1 Sep 25	H2 Mar 25	H1 Sep 24
Revenue	1.3	0.8	0.8	1.2
Gross profit	1.0	0.2	0.1	0.3
EBITDA	–	(0.5)	(0.9)	(0.7)
Operating profit	(0.6)	(0.5)	(0.8)	(0.8)
Share-based payments	0.1	0.0	0.0	0.0
Finance costs	(0.0)	(0.0)	(0.0)	(0.0)
Profit before tax	(0.6)	(0.5)	(0.8)	(0.8)
Tax	–	0.0	0.0	0.0
Net income (owners)	(0.6)	(0.5)	(0.9)	(0.8)
EPS basic	(0.7p)	(0.5p)	(0.9p)	(0.8p)

	FY Mar 26	FY Mar 25
Cash from operations	(1.1)	(1.4)
Interest paid	0.0	(0.0)
Capex (PP&E)	(0.1)	(0.0)
Shares issued	1.9	0.6

	H2 Mar 26	H1 Sep 25	H2 Mar 25	H1 Sep 24
Cash from operations	(0.5)	(0.6)	(0.6)	(0.8)
Interest paid	0.0	(0.0)	(0.0)	(0.0)
Capex (PP&E)	0.0	(0.1)	(0.0)	0.0
Shares issued	1.4	0.6	0.6	0.0

	FY Mar 26	FY Mar 25
Property, plant & equipment	0.4	0.1
Inventories	0.4	0.3
Trade receivables	0.8	0.7
Cash	1.0	0.4
Current assets	2.4	1.3
Total assets	2.7	1.4
Trade payables	0.7	0.6
Borrowings, current	0.1	0.0
Current liabilities	0.8	0.6
Borrowings, non-current	0.2	0.0
Total liabilities	1.1	0.7
Total equity	1.6	0.8

	H2 Mar 26	H1 Sep 25	H2 Mar 25	H1 Sep 24
Property, plant & equipment	0.4	0.4	0.1	0.1
Inventories	0.4	0.3	0.3	0.2
Trade receivables	0.8	0.9	0.7	0.8
Cash	1.0	0.3	0.4	0.4
Current assets	2.4	–	1.3	–
Total assets	2.7	1.8	1.4	1.5
Trade payables	0.7	0.7	0.6	0.4
Borrowings, current	0.1	0.1	0.0	0.0
Current liabilities	0.8	–	0.6	–
Borrowings, non-current	0.2	0.3	0.0	0.0
Total liabilities	1.1	1.1	0.7	0.5
Total equity	1.6	0.7	0.8	1.1

Line items extracted automatically from each results announcement; when a later report restates a period, the later figure is shown. LTM and H2 are calculated from reported periods. Check the source before relying on a figure.

Company filings. Not investment advice.